UK route of administration of recombinant vaccinia vitas (rVV) vaccines effects the active treatment of cancer

Kari R. Irvine, Ronald S. Chamberlain, Vincenzo Bronte, Steven A. Rosenberg, Nicholas P. Restifo

Research output: Contribution to journalArticlepeer-review


To evaluate the effect of the route of immunization using rVV as immunogens for the treatment of established pulmonary métastases, we employed an experimental murine tumor, CT26, expressing the model tumor-associated antigen, β-galactosidase (β-gal), designated CT26.CL25 BALB/c mice were administered 10'PFU of rW encoding β-gal via intravenous (IV), intramuscular (IM), intradermal (ID), or via tail scarification (TS) route of administration 3 days following tumor inoculation. Twelve day lung métastases were enumerated in a blinded fashion. The cumulative results of four separate studies have revealed that a significant reduction in the average number of métastases was observed in the groups that received rW immunizations either IV (with an average number of 20 metastases/mouse) or IM (46 métastases) versus mice that received no immunization (246). Surprisingly, scarification (146), the usual route of immunization of rVV, and ID (142) were not significantly effective. When using the molecularly defined adjuvant, IL-2, in conjunction with these studies, the IV route of immunization was still significantly more effective than other routes evaluated. These data suggest that IV or IM administration of rVV may be the most effective method of immunization to use in the design of clinical trials using rVV anti-cancer vaccines.

Original languageEnglish (US)
Pages (from-to)A1470
JournalFASEB Journal
Issue number6
StatePublished - Dec 1 1996

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics


Dive into the research topics of 'UK route of administration of recombinant vaccinia vitas (rVV) vaccines effects the active treatment of cancer'. Together they form a unique fingerprint.

Cite this